[
  {
    "human": "Given this context, can you construct a suitable explanation for me to relay to my boss?"
  },
  {
    "gpt": "The financial summary table shows data for a company, possibly 23andMe, over a range of fiscal years from FY19A (actual) to FY24E (estimated). Here's a suitable explanation for each data point:\r\n\r\n1. **Cumulative Genotyped Customers**: This figure represents the total number of customers who have had their genotypes analyzed by the company's services. It has been growing steadily from 7.8 million in FY19A to 12.6 million in FY22E. The company projects this number to increase to 14.3 million in FY23E and 16.4 million in FY24E.\r\n\r\n2. **Cumulative Subscribers**: This line is absent for FY19A and FY20A, indicating the subscription service may have been introduced in FY21. It started at 0.1 million in FY21E, increased to 0.7 million in FY22E, and is expected to grow to 1.6 million in FY23E and nearly double to 2.9 million in FY24E. This could imply a successful uptake of a subscription-based model.\r\n\r\n3. **Revenue**: Revenue has fluctuated, with a noticeable drop from $441 million in FY19A to $218 million in FY21E before rising again to $256 million in FY22E. Projections show a positive trend with an anticipated increase to $317 million in FY23E and $400 million in FY24E, possibly due to the growth in genotyped customers and subscribers.\r\n\r\n4. **Gross Margin %**: This indicates the percentage of revenue remaining after accounting for the costs of goods sold. The margin has been fairly stable at 44%-45% in FY19A through FY21E and shows an improvement in FY22E at 51%, with a forecast to further improve to 55% in FY23E and 58% in FY24E. This suggests increasing efficiency or a higher premium on products\/services.\r\n\r\n5. **Adjusted EBITDA (Consumer & Research Services)**: This figure represents the earnings before interest, taxes, depreciation, and amortization, adjusted for the consumer and research segments of the business. It was negative across all years, meaning expenses exceeded revenue in this segment. However, there's an improving trend from -$86 million in FY19A to -$10 million in FY22E, turning positive in projections for FY23E at $26 million and substantially increasing to $71 million in FY24E.\r\n\r\n6. **Adjusted EBITDA**: This is the company's overall earnings before the mentioned deductions, adjusted for exceptional items. It was negative from FY19A to FY22E but is expected to be less negative in future projections, improving from -$141 million in FY19A to -$78 million in FY24E.\r\n\r\nIn summary, while the company faced challenges with revenue and profitability in the past, the projections indicate growth in customer base, an improvement in gross margins, a turnaround in the consumer and research segments' profitability, and a general improvement in overall EBITDA. This suggests a strategic direction that is starting to yield positive results, with expectations of continued growth and profitability improvement in the future."
  }
]